Today: 9 June 2026
L3Harris stock in focus after Pentagon’s $1B missile-unit deal tees up 2026 IPO
14 January 2026
2 mins read

L3Harris stock in focus after Pentagon’s $1B missile-unit deal tees up 2026 IPO

New York, Jan 13, 2026, 20:08 EST — Market closed.

  • The Pentagon is set to make a $1 billion convertible investment in L3Harris Missile Solutions, aiming for an IPO in the latter half of 2026
  • L3Harris shares ended close to unchanged following an initial surge on the news
  • Investors are focused on deal mechanics, Washington oversight, and L3Harris results due later this month

L3Harris Technologies, Inc. announced the Pentagon will invest $1 billion in its Missile Solutions unit, paving the way for that segment to spin off as a separate publicly traded company. An IPO is planned for the second half of 2026. On Tuesday, L3Harris shares edged up about 0.2%, closing at $341.24.

This shift matters because it brings the government nearer to the production line. Rather than depending solely on contracts, the Pentagon aims to secure the supply of solid rocket motors — a critical bottleneck in missile manufacturing — by adopting a setup resembling project finance instead of the usual procurement methods.

The move underscores urgency. The Pentagon is promoting the investment as a “direct-to-supplier” model aimed at accelerating capacity growth, though it still requires Congress to approve funding and authorizations for full-scale production, officials noted. L3Harris CEO Chris Kubasik said the department won’t take a board seat and will view it purely as a financial investment. Breaking Defense

L3Harris plans to retain a controlling stake in Missile Solutions after the deal closes. The company expects the unit to gain from ongoing demand linked to programs like PAC-3, THAAD, Tomahawk, and Standard Missile. J.P. Morgan Securities is acting as its financial adviser, with Vinson & Elkins serving as legal counsel for the proposed transaction.

Defense News reported that L3Harris CFO Ken Bedingfield told investors the company’s sales could more than double by decade’s end. Bryan Clark, a senior fellow at the Hudson Institute, said the spin-off might revive a “pure-play” rocket-motor supplier and give the government a cleaner handle on the supply chain. But he also warned that demand swings could leave a standalone producer vulnerable. Defense News

The deal comes amid a tight market. Northrop Grumman remains another major U.S. rocket-motor maker, but TD Cowen analyst Gautam Khanna flagged that a government-backed competitor could put others at a disadvantage. Reuters noted the setup is unusual for defense, potentially raising concerns about conflicts of interest since the government would hold an equity-linked stake in a contractor bidding for federal contracts.

Traders will be eyeing the next session to see if cash continues flowing into defense supply-chain stocks or if interest drops after an initial surge. The real issue isn’t just valuation but whether Washington will repeat this playbook.

There’s plenty that could derail this. The deal hinges on a letter of intent and a set IPO schedule, while the Pentagon warns that multi-year procurement depends on Congress approving funds. Plus, rival contractors might fight back if they sense the odds aren’t even.

Inside L3Harris, the landscape is evolving. This month, the company restructured into three segments, elevating “Missile Solutions” to its own business line under Bedingfield’s leadership. L3Harris® Fast. Forward.

On Jan. 29, L3Harris will release its fourth-quarter 2025 results before the market opens, followed by an earnings call at 10:30 a.m. ET. This report will be a key moment to gauge how management addresses the IPO plan, capital requirements, and demand outlook.

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Google stock (GOOG) rises after-hours on Apple’s Gemini-Siri deal as earnings near
Previous Story

Google stock (GOOG) rises after-hours on Apple’s Gemini-Siri deal as earnings near

BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP
Next Story

BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP

Go toTop